GIGABYTE-TECHNOLOGY
4.6.2021 11:38:50 CEST | Business Wire | Press release
GIGABYTE Technology, a leading brand of computer innovations, continues its strong presence at COMPUTEX, joining the “#COMPUTEXVirtual” platform as the exhibition takes place online due to global pandemic situation. From May 31st to June 30th , GIGABYTE orchestrated 10 different sections in a dedicated “GIGABYTE Pavilion” to exhibit a series of products and solutions that can expand on its “Bring Smart to Life” concept, from the data center to personal computer, and 5G to edge AI computing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210604005208/en/
GIGABYTE is known for having the most extensive portfolio of AMD servers for demanding workloads, and has readied a comprehensive lineup of servers supporting the 7nm processor, unlocking its incredible performance of up to 64 cores and 128 threads to enable developers and scientists to tackle challenges in HPC and cloud computing. Correspondingly, GIGABYTE is primed to present Intel servers based on the latest 3rd Gen. Intel® Xeon® Scalable Processors suited for enterprises looking to upgrade their IT infrastructure.
At the forefront of server development is an NVIDIA Arm HPC Developer Kit, a system that includes an Ampere Altra processor, two NVIDIA A100 Tensor Core GPUs, and two NVIDIA BlueField®-2 DPUs, all contained in a leading-edge GIGABYTE G242 server. In addition, GIGABYTE will present four ARM server products, all of which can leverage the power of the 80-core (250W) Ampere Altra processors to provide outstanding efficiency, performance, and throughput.
Smart cities benefited from the computing power of data centers through GIGABYTE’s industrial motherboards, embedded systems, automotive electronics, 3D depth sensing solutions, visual recognition solutions, and deep learning-based AI training and inferencing programs. Notable exhibits will include Industry 4.0 factory automation and smart retail solutions, in-vehicle ECU and AI edge computing platforms, and AI facial recognition systems.
PC consumers are treated with AORUS and AERO premium laptops, now powered by Intel’s latest 11th Gen Tiger Lake-H series processors, while pairing with the full-power RTX 30 series graphics cards and 4K OLED panels respectively; new AORUS 4K gaming monitors equipped with exclusive tactical game-enhancement features and HDMI 2.1-ready for full support of the new-gen gaming consoles; and two prebuilt AORUS flagship systems that are the world’s first factory-tuned gaming desktops, with the most powerful component to date, and tuned and tested to ensure impeccable stability and performance out of the box.
Visit “GIGABYTE Pavilion”
https://virtual.computextaipei.com.tw/area/gigabyte/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210604005208/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom